Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930370 | 0.84 | PDE7A (0.59) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL875772 | 0.82 | PDE7A (0.78) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31272173 | 0.82 | PDE7A (0.78) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2360372 | 0.80 | PDE7A (0.59) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9775860 | 0.79 | TSHR (0.59) | SMN1; SMN2TSHRGPR35ALDH1A1TDP1 | |
| Fluoride SCHEMBL946835 | 0.77 | TSHR (0.57) | SMN1; SMN2TSHRGPR35ALDH1A1TDP1 | |
| SCHEMBL9709555 | 0.77 | PDE7A (0.58) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22133428 | 0.73 | ALDH1A1 (0.65) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3192750 | 0.73 | GPR35 (0.57) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2417324 | 0.73 | PDE7A (0.64) | PDE7ASMN1; SMN2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010134992-A2 | SYNTHESIS LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010062404-A2 | N-FMOC NUCLEOSIDES AND PHOSPHORAMIDITES, AND OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20070054888-A1 | NOVEL SUBSTITUTED DIAMINE DERIVATIVES USEFUL AS MOTILIN AGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1003774-B1 | GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 | FERRING BV (NL) | 2006-03-08 | — | — | EP | disclosed |
| EP-0973801-B1 | GnRH ANTAGONISTS | FERRING BV (NL) | 2002-12-18 | — | — | EP | disclosed |
| EP-0794959-B1 | AMINO ACIDS FOR MAKING BETIDES AND METHODS OF SCREENING AND MAKING BETIDE LIBRARIES | SALK INST FOR BIOLOGICAL STUDI (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0973801-A1 | GnRH ANTAGONISTS | FERRING B.V. (NL) | 2000-01-26 | — | — | EP | disclosed |
| US-5925730-A | GnRH antagonists | FERRING BV (NL) | 1999-07-20 | — | — | US | disclosed |
| US-4652550-A | INHIBITING RELEASE OF GONADOTROPINS; PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0201260-A2 | GnRH antagonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-11-12 | — | — | EP | disclosed |
| US-4619914-A | PEPTIDES WHICH INHIBIT GONADOTROPIN SECRETION-CONTRACEPTIVES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-10-28 | — | — | US | disclosed |
| EP-0192492-A2 | Peptides containing an aliphatic-aromatic ketone side chain | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0175506-A2 | GnRH antagonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4569927-A | INHIBITING SECRETION OF GONADOTROPINS AND STEROIDS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-02-11 | — | — | US | disclosed |
| US-4565804-A | GnRH Antagonists VI | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-01-21 | — | — | US | disclosed |
| EP-0162575-A2 | GnRH Antagonists VII | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1985-11-27 | — | — | EP | disclosed |
| EP-0122712-A2 | GnRH antagonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1984-10-24 | — | — | EP | disclosed |
| US-4013791-A | MEDICAL DIAGNOSIS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054888-A1 | NOVEL SUBSTITUTED DIAMINE DERIVATIVES USEFUL AS MOTILIN AGONISTS | MLNR, NPY4R, GIPR | PDE7A 827/4885SMN1; SMN2 2280/4885SLC6A2 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.